2.1.1.8 Patients must have normal organ and marrow function as defined below: o Serum creatinine ≤ 1.5 x upper limit of normal OR creatinine clearance on a 24-h urine collection of ≥ 50 mL/min. o ALT and AST ≤ 3x the upper limits of normal. o Total bilirubin ≤ 1.5 x upper limit of normal OR in patients with Gilbert’s syndrome , a total bilirubin ≤ 3.0. o Hematological eligibility parameters (within 16 days of starting therapy): • Granulocyte count ≥ 1,500/mm3 • Platelet cou nt ≥ 100,000/mm3 2.1.1.9 Patients must have baseline pulse oximetry > 90% on room air. 2.1.1.10 The effects of MVA -brachyury- TRICOM on the developing human fetus are unknown. For this reaso n, women of child-bearing potential and men must agree to use adequate contracepti on (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for a period of 4 months aft er the last vaccination therapy . Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 2.1.1.11 Patients with prostate cancer must continue to receive GnRH agonist therapy (unless orchiectomy has been done). If a patient has refused GnRH therapy, t hey may be enrolled on a dose level for which the safety has already been determined. Patients must be able to understand and be willing to sign a written informed consent document.